Hongdoushan A

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Hongdoushan A
• 英文别名: [(1S,2S,3S,5S,8S,10S,14S)-2,5-diacetyloxy-10-hydroxy-8,12,15,15-tetramethyl-4-methylidene-14-tricyclo[9.3.1.03,8]pentadec-11-enyl] (2S)-2-methylbutanoate
• 化学式: C₂₉H₄₄O₇
• 分子量: 504.7
• InChiKey: HULFDGRJZFOLFD-BNKKXMPWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  99.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• [EN] METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE D'INHIBITEURS ROR GAMMA
  申请人：UNIV CALIFORNIA

  公开号：WO2017127442A1

  公开（公告）日：2017-07-27

  The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.

  本发明提供了包含一种或多种I式化合物的组合物、方法和试剂盒，例如XY018，单独或与一种或多种抗癌药物（如抗雄激素药物）结合使用，用于治疗癌症，例如前列腺癌，如去势抵抗性前列腺癌（CRPC），以及包括肺癌、乳腺癌、肝癌、卵巢癌、子宫内膜癌、膀胱癌、结肠癌、胃癌、淋巴瘤和胶质瘤在内的许多其他类型的癌症。
• [EN] CYANINE-BASED TELODENDRIMERS AND USES FOR TREATING CANCER<br/>[FR] TÉLODENDRIMÈRES À BASE DE CYANINE ET UTILISATIONS POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CALIFORNIA

  公开号：WO2020047418A1

  公开（公告）日：2020-03-05

  The present invention provides a cyanine modified telodendrimer, nanoparticles thereof, and methods of using the nanoparticles to treat various diseases such as cancer.

  本发明提供了一种靛蓝改性的端树聚合物，以及其纳米颗粒，以及使用这些纳米颗粒治疗癌症等各种疾病的方法。
• [EN] CX3CR1 SMALL MOLECULE ANTAGONISTS, AND METHODS USING SAME<br/>[FR] ANTAGONISTES DE CX3CR1 À PETITES MOLÉCULES, ET PROCÉDÉS LES UTILISANT
  申请人：UNIV DREXEL

  公开号：WO2018204370A1

  公开（公告）日：2018-11-08

  The invention provides compounds that are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.

  该发明提供了一些是分叉粘附分子受体激动剂的化合物，用于治疗、预防或减少诊断为癌症的受试者体内的转移。该发明的化合物还可用于治疗中枢神经系统疾病（例如，但不限于，HIV相关神经认知障碍（HAND）和/或阿尔茨海默病）、疼痛、炎症（例如，但不限于，关节炎）、心血管疾病（例如，但不限于，不良血管平滑肌增殖、动脉粥样硬化、冠状血管内皮功能障碍和/或冠心病）和/或多发性硬化。
• [EN] BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT<br/>[FR] BIAMINOQUINOLINES ET NANOFORMULATIONS POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CALIFORNIA

  公开号：WO2021055705A1

  公开（公告）日：2021-03-25

  The present invention provides bisaminoquinoline compounds of Formula (I). The present invention also provides nanocarriers comprising compounds of the present invention, and methods of using the nanocarriers for treating diseases and imaging.

  本发明提供了式（I）的双氨基喹啉化合物。本发明还提供了包含本发明化合物的纳米载体，以及利用这些纳米载体用于治疗疾病和成像的方法。

表征谱图